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Abstract: BACKGROUND Endothelial cells regulate the formation of blood clots thus, genes selectively
expressed in these cells could primarily determine thrombus formation. Apold1(apolipoprotein L domain
containing 1) is a gene expressed by endothelial cells; whether Apold1 directly contributes to arterial
thrombosis has not yet been investigated. Here, we assessed the effect of Apold1 deletion on arterial
thrombus formation using an in vivo model of carotid thrombosis induced by photochemical injury.
MATERIAL AND METHODS Apold1 knockout (Apold1-/- ) mice and wild type (WT) littermates un-
derwent carotid thrombosis induced by photochemical injury and time to occlusion was recorded. Tissue
factor (TF) activity as well as activation of mitogen-activated protein kinases (MAPKs) and phosphatidyl-
inositol-3 kinase (PI3K)/Akt pathways were analyzed by colorimetric assay and western blotting in both
Apold1-/- and WT mice. Finally, platelet reactivity was assessed using light transmission aggregometry.
RESULTS After photochemical injury, Apold1−/− mice exhibited shorter time to occlusion as compared
to WT mice. Moreover, TF activity was increased in carotid arteries of Apold1−/− when compared to
WT mice. Underlying mechanistic markers such as TF mRNA and MAPKs activation were unaffected
in Apold1−/− mice. In contrast, phosphorylation of Akt was reduced in Apold1−/− as compared to WT
mice. Additionally, Apold1−/− mice displayed increased platelet reactivity to stimulation with collagen
compared to WT animals. CONCLUSIONS Deficiency of Apold1 results in a prothrombotic phenotype,
accompanied by increased vascular TF activity,decreased PI3K/Akt activation and increased platelet re-
activity. These findings suggest Apold1 as an interesting new therapeutic target in the context of arterial
thrombosis.
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Background: Endothelial cells and platelets play a fundamental role in regulating the formation of 
blood clots thus, genes selectively expressed in these cells could primarily determine thrombus 
formation. Apold1(apolipoprotein L domain containing 1) is a gene whose expression is confined to 
endothelial cells. However, whether Apold1 directly contributes to arterial thrombosis has not yet been 
investigated. Therefore, the purpose of this study was to assess the effect of Apold1 deletion on arterial 
thrombus formation using an in vivo model of carotid artery thrombosis induced by photochemical 
injury. 
Material and methods: Apold1 knockout (Apold1-/-) mice and wild type (WT) littermates underwent 
carotid thrombosis induced by endothelial specific photochemical injury. Time to occlusion was 
measured in the right carotid artery of both groups. In addition, tissue factor (TF) activity was assessed 
in the left carotid artery and plasma. Activation of mitogen-activated protein kinases (MAPKs) and 
phosphatidyl-inositol-3 kinase (PI3K)/Akt pathways were analyzed by Western blotting in aortas of 
Apold1-/- and WT mice. Finally, platelet reactivity in Apold1-/- and WT mice was assessed using light 
transmission aggregometry.Results: After photochemical injury, Apold1-/- mice exhibited shorter time 
to occlusion as compared to WT mice. Moreover, TF activity was increased in carotid arteries of 
Apold1-/- when compared to WT mice. Underlying mechanistic markers such as TF mRNA and 
MAPKs activation were unaffected in Apold1-/- mice. In contrast, phosphorylation of Akt was reduced 
in Apold1-/- as compared to WT mice. Additionally, Apold1-/- mice displayed increased platelet 
reactivity to stimulation with collagen compared to WT animals. 
Conclusions: Deficiency of Apold1 results in a prothrombotic phenotype, accompanied by increased 
vascular TF activity,decreased PI3K/Akt activation and increased platelet reactivity. These findings 






The formation of blood clots obstructing circulation in vital organs such as the heart and brain 
represents a major cause of death worldwide.1 Specifically, arterial thrombosis triggered by 
endothelial erosion or plaque rupture, referred to as atherothrombosis, is a key mediator of myocardial 
infarction and ischemic stroke.1 The pathophysiology of atherothrombosis involves elements 
pertaining to the atherosclerotic process in itself as well as its interaction with thrombotic 
complications.2 Indeed, the atherosclerotic plaque composition determines the risk of plaque 
disruption.2 In particular, high levels of tissue factor (TF), the main procoagulant protein, within the 
atherosclerotic lesion increase a plaque´s thrombogenicity.3 Upon rupture of the plaque, the pathways 
that regulate platelet activation and fibrin (the final protein of the coagulation cascade) formation are 
intrinsically associated in the formation of a thrombus.3, 4 In this regard, the COMPASS trial recently 
provided empirical evidence supporting the use of combined antiplatelet and anticoagulant therapy for 
reducing cardiovascular events and death in patients with atherosclerotic disease.5, 6 These findings 
update the classical view, which recommends the use of  antiplatelet in preference to anticoagulant 
therapy for secondary cardiovascular prevention.3, 7, 8 With the new treatment paradigm, exploring new 
genes associated with antiplatelet and anticoagulant properties, with minor impact on bleeding risk, is 
considered to be a priority in the cardiovascular field.3, 9, 10 
 Apolipoprotein L domain-containing protein 1 (Apold1), also known as vascular early response gene, 
is a gene identified in endothelial cells11 that responds to different stimuli such as ischemia, cytokines, 
growth factors and stress.12, 13 Genes selectively expressed in endothelial cells could primarily 
determine thrombus formation.10, 14 However, whether Apold1 directly contributes to thrombosis has 
not yet been investigated. Therefore, the purpose of this study was to assess the effect of Apold1 on 





Material and methods 
Animals 
Experiments were performed with 11–15-week-old male Apold1 knockout (Apold1-/-) mice and wild-
type (WT) control C57Bl6/J littermates. In the Apold1(-/-) mice, the open reading frame was replaced 
with a beta-gal/neo cassette.15 These mice were generously provided by Dr. Paul Worley and 
backcrossed to C57Bl6/J mice for more than 6 generations. Genotype confirmation was performed by 
PCR using the following primers:F2 5′-CTCTAGCCTAGGGCAGCAAC-3′; wtR1 5′-
GAGAGAGGTCGGACGTGATG-3′; LacZR 5′-GGCGATTAAGTTGGGTAACG-3′ (Regard and 
Worley, unpublished data). PCR cycling was performed at 95°C for 5 min followed by 45 cycles at 
95°C for 30 s, 64°C for 30 s, 72°C for 30 s and finally 72°C for 5 min, by using Taq DNA polymerase 
(Sigma-Aldrich, D1806-1.5KU) supplemented with 1M Betaine (Sigma-Aldrich, B0300-1VL). PCR 
products were analyzed by 2% agarose gel electrophoresis. Study design and experimental protocols 
were approved by the institutional animal care committee (License no. TVA 153_2018 Kommission 
für Tierversuche des Kantons Zürich, Switzerland).   
Laser-induced carotid thrombosis in vivo 
In vivo mouse carotid thrombosis was induced as previously described.16-18 Briefly, animals were 
anaesthetized using 87 mg/kg sodium pentobarbital (Butler, Columbus, OH, USA). The right common 
carotid artery was exposed following a midline cervical incision. A Doppler flow probe (Transonic 
Systems, Ithaca, NY, USA) connected to a flowmeter (Model T106, Transonic Systems, Ithaca, NY, 
USA) was used for continuous assessment of carotid blood flow and heart rate. To induce 
photochemical injury of the endothelium, Rose Bengal (63 mg/kg body weight) was injected into the 
tail vein and the right common carotid artery was exposed to a laser light beam (1.5 mW, 540 nm, 
Mellesgriot Inc., Carlsbad, CA, USA) at a distance of 6 cm for 60 min. Blood flow was monitored 
from laser onset for maximum 120 min, or until occlusion (flow ≤0.1 mL for 1 min) occurred. During 
the experimental period, the operator was blinded to the animal group allocation. After thrombosis, 
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animals were euthanized by inhalation of an isoflurane overdose to allow the harvesting of blood and 
carotid arteries. 
Tissue factor activity assay 
 TF activity was determined as previously described19, 20 in murine plasma and left carotid arteries 
from Apold1-/- and WT mice by colorimetric assay, according to the recommendation of the 
manufacturer (American Diagnostica, Stamford, CT, USA). Blood was collected via intracardiac 
puncture and immediately mixed with EDTA, the EDTA-blood solution was then centrifuged for 15 
min at 3000 g. EDTA-plasma was collected and snap frozen in liquid nitrogen. Carotid arteries were 
lysed (50mmol/L Tris–HCl, 100mmol/L NaCl, 0.1% Triton X-100, pH 7.4), and total protein 
concentration was determined by Bradford protein assay according to the manufacturer’s 
recommendations (VWR Life Science AMRESCO, Solon, OH, USA). EDTA-plasma and carotid 
lysates were mixed with factor VIIa and X which leads to the conversion of factor X to Xa; factor Xa 
subsequently cleaves the chromogenic substrate SPECTROZYME FXa. Optical density of cleaved 
SPECTROZYMEV FXa was determined at 490 nm by Nanodrop 2000 Spectrophotometer (Thermo 
Scientific, Waltham, MA, USA) and subtracted from absorbance at 405 nm. Finally, TF (pM) content 
was calculated, according to a standard curve. For carotid lysates, TF concentration as detected by the 
colorimetric assay was normalized to the total protein content of the sample and expressed as pM/g of 
total protein. 
Collagen-induced platelet aggregation in mice 
For platelet aggregation studies, washed platelets were obtained from 3.8 % citrate anticoagulated 
blood after euthanasia, as previously described21.Thereafter, washed platelets were re-suspended in 
Thyrode’s buffer (134 mM NaCl; 0.34 mM Na2HPO4; 2.9 mM KCl; 12 mM NaHCO3; 20 mM 
Hepes; 5 mM glucose; 0.35% (w/v) bovine serum albumin; pH 7.0) and platelet counts were 
normalized to 200’000/µl. Platelets were activated with collagen (final concentration 5 µg/ml) and 
maximal aggregation (%), lag phase (s) and slope of aggregation (%/min) were assessed using light 
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transmission aggregometry (APACT 4004 aggregometer, Haemochrom Diagnostica GmbH, Essen, 
Germany). 
Blood cell counts 
Total blood cell count was performed on a ScilVet ABCplus (Horiba, Kyoto, Japan) using EDTA-
anticoagulated blood. 
Western Blotting 
Protein expression was determined by Western blot analysis as previously described.22, 23 Aortae were 
homogenized in lysis buffer (Tris 50 mM, NaCl 150 mM, EDTA 1 mM, NaF 1 mM, DTT 1 mM, 
aprotinin 10 mg/mL, leupeptin 10 mg/mL, Na3VO4 0.1 mM, phenylmethylsulfonyl fluoride (PMSF) 1 
mM, and NP-40 0.5%). Protein concentration was determined according to the manufacturer’s 
recommendations (VWR Life Science AMRESCO, Solon, OH, USA); 20 – 30 µg of total protein 
lysates were separated on an 8 or 10% SDS–PAGE before being transferred to a polyvinylidene 
fluoride membrane by wet transfer (Bio-Rad). Membranes were incubated with primary antibodies 
against phospho-Akt (1:1000, Cell Signaling, Beverly, MA, USA), Akt (1:1000, Cell Signaling, 
Beverly, MA, USA),  phospho-p38 (1:500, Cell Signaling, Beverly, MA, USA), p38 (1:1000, Cell 
Signaling, Beverly, MA, USA), phospho- c-Jun N-terminal kinase (JNK) (1:1000, Cell Signaling, 
Beverly, MA, USA), JNK (1:1000, Cell Signaling, Beverly, MA, USA), phospho-extracellular-signal-
regulated kinase (ERK) (1:1000, Cell Signaling, Beverly, MA, USA), ERK (1:1000, Cell Signaling, 
Beverly, MA, USA) at 4°C overnight on a shaker. Secondary antibodies (Southern Biotechnology, 
Birmingham, AL, USA) were applied for 1 h at room temperature. Densitometric analyses were 
performed (Amersham Imager 600, GE Healthcare Europe GmbH, Glattbrugg, Switzerland) and 
protein expression of the phosphorylated protein was normalized to the total one. 
Quantitative Real-Time Polymerase Chain Reaction (RT-PCR) 
Total RNA was extracted from aortae using TRI reagent (Sigma-Aldrich, Buchs, Switzerland), 
according to the recommendations of the manufacturer. Conversion of the total cellular RNA to cDNA 
was performed with Moloneymurine leukaemia virus reverse transcriptase and random hexamers (GE 
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Healthcare, Chicago, IL, USA) in a final volume of 35 µl, using 2 µg of total RNA, according to 
recommendations of the manufacturer. RT-PCR was performed in a QuantStudio 7 Flex RT-PCR 
cycler (Applied BiosystemsTM, Foster City, CA), according to the instructions of the manufacturer. 
All RT- PCR experiments were performed using the SYBR Select Master Mix provided by Applied 
Biosystems (Life Technologies, Carlsbad, CA, USA). Each reaction (20 µl) contained 2 µl cDNA, 1µl 
of each primer and 10 µl of Master Mix. The amplification  program consisted of 1 cycle at 95ºC for 
10 min, followed by 40 cycles with a denaturing phase at 95ºC for 15s and an annealing/elongation 
phase at 60ºC for 1 min. Cycle threshold (Ct) values for each gene were obtained for each sample and 
differences in Ct values between a test gene and endogenous controls were calculated and used for 
statistical analyses. For quantitative RT-PCR, the following primers were used; for mouse TF: sense 
primer (1) 50-CTTTCTCATGTCCAGGGT-30, antisense primer (1) 50-
GTTGCCAAACCTCTTTGT-30 and GAPDH: (1) 50-CTTTCTCATGTCCAGGGT-30, antisense 





Deficiency of Apold-1 accelerates time to arterial thrombotic occlusion  
To evaluate the role of Apold1 in arterial thrombosis, Apold1-/- and WT mice underwent endothelial 
injury by generating reactive oxygen species using a photoreactive dye (i.e. Rose Bengal). Body 
weight (WT: 28.91 ± 0.66 g vs.  Apold1-/-: 29.19 ± 0.56 g; P >0.05; n=12-14, Figure 1A), initial heart 
rate (WT: 264.3 ± 8.80 bpm/min vs. Apold1-/-: 289.2 ± 12.63 bpm/min; P >0.05; n=12-13, Figure 1B) 
and initial carotid blood flow (WT: 0.59 ± 0.036 ml/min vs. Apold1-/-: 0.59 ± 0.029 ml/min; P >0.05; 
n=12-14, Figure 1C) did not differ between groups. WT  mice developed carotid artery thrombosis 
within a mean time of 39.96 ± 3.86 min, while Apold1-/- mice occluded within a mean time of 29.42 ± 
2.74 min (P < 0.05; n=12-14, Figure 2D,E).  
Deficiency of Apold-1 increases TF activity and decreases phosphatidyl-inositol-3 kinase 
(PI3K)/Akt activation, but does not affect TF mRNA levels and mitogen-activated protein 
kinases (MAPKs) activation  
To investigate the mechanisms underlying the prothrombotic phenotype observed in Apold1-/- mice, 
TF expression and activity was assessed in Apold1-/- and WT mice. Deficiency of  Apold1 did not 
affect TF gene expression (WT: 0.04 ± 0.016 ∆Ct vs. Apold1-/-: 0.02 ± 0.003 ∆Ct; P > 0.05; n=6-8, 
Figure 2A), but increased TF activity in the carotid artery  (WT:13.48 ± 3.20 pM/g vs. Apold1-/-: 
27.31 ± 4.55 pM/g; P <0.05; n=10, Figure 2B). In addition plasma levels of TF did not differ between 
groups (WT:183.9 ± 45.92 pM vs. Apold1-/-: 308.0 ± 59.33 pM; P >0.05; n=9-10, Figure 2C).To 
assess the potential mechanisms explaining the higher TF activity in Apold1-/- mice,  we evaluated the 
signaling pathways regulating TF. Activation of  MAPK, p38 (WT:1.41 ± 0.169 AU vs. Apold1-/-: 1.32 
± 0.178 AU; P > 0.05; n=8-9, Figure 2D), JNK (WT:1.00 ± 0.236 AU vs. Apold1-/-: 0.80 ± 0.101 AU; 
P > 0.05; n=7-9, Figure 2E), and ERK (WT:0.397 ± 0.184 AU vs. Apold1-/-: 0.196 ± 0.057 AU; P > 
0.05; n=6-7, Figure 2F), which regulate TF at transcriptional level, were unaffected by deletion of 
Apold1. Further, we evaluated the activation status of the PI3K/Akt pathway, a negative regulator of 
TF which functions at both the transcriptional or post-transcriptional level. Importantly, the activation 
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of Akt, assessed as the ratio between phosphorylated Akt and total Akt, was decreased in the arteries 
of Apold1-/- mice as compared to WT mice (WT:1.46 ± 0.289 AU vs. Apold1-/-: 0.77± 0.143 AU; P 
<0.05; n=6-8, Figure 2G). 
Deficiency of Apold-1 increases platelet reactivity to collagen 
Given the importat role played by platelets in arterial thombus formation, we investigated whether 
Apold-1  deficiency affects platelet count and function. Complete blood count analyses revealed that 
platelet number (WT:766 ± 20 103/mm3 vs. Apold1-/-: 814 ± 61.63 103/mm3 ; P > 0.05; n=9-10, Figure 
3A) and volume (WT:7.03 ± 0.33 fl vs. Apold1-/-: 6.77 ± 0.32 fl; P > 0.05; n=9-10, Figure 3B) were 
unchanged in Apold1-/- mice. In addition, reactivity of washed platelets to collagen was assessed by 
light transmission aggregometry. Deficiency of Apold-1 enhanced collagen-induced platelet reactivity 
as demonstrated by increased maximal aggregation (WT:40.46 ± 5.93 % vs. Apold1-/-: 68.49 ± 6.88 %; 
P < 0.05; n=9-10, Figure 3C), increased rate (slope) of aggregation (WT:16.79 ± 3.5 %/min vs. 
Apold1-/-: 47.13 ± 12.35; P < 0.05; n=9-10, Figure 3D) and decreased lag phase (WT:175.5 ± 24.05 s 





This study assessed the role of a gene specifically expressed in endothelial cells, Apold1, in arterial 
thrombosis using an in vivo mouse model of arterial thrombus formation relying on a laser induced 
endothelial-specific vascular injury. The main findings are: 1) Apold1 deficiency leads to increased 
arterial thrombus formation in the carotid artery, 2) arterial TF activity is increased while PI3K 
activation is decreased and 3) platelet reactivity is increased in response to collagen. These results 
denote Apold1 as a novel gene regulating arterial thrombosis by acting on the coagulation cascade and 
platelet activation.  
Little is known about the function of Apold1 in health and disease, however it appears to be involved 
in several biological processes. Loss of Apold1 reduces oedema formation in a mouse model of 
stroke,15 and angiogenesis and neurogenesis in long-term recovery from neonatal stroke.11 
Additionally, intense physical activity as well as stress exposure strongly activate Apold1 expression 
in the heart and in the brain, 24,25  and the stress-induced increase is mediated by beta2-adrenergic 
receptors.13 The regulation by adrenoceptors might explain why various physiological stimuli can 
trigger Apold1 expression. Despite its widespread involvement in different biological functions, 
Apold1 deficient mice are healthy and appear to have no overt behavioral alterations.11, 15 Accordingly, 
Apold1 may not be essential under physiological conditions, however, whether Apold1 plays crucial 
functions under pathological conditions deserves further investigation. 
In the present study, our results demonstrated a protective role of Apold1 in arterial thrombosis. TF 
activates the extrinsic coagulation cascade following the disruption of vascular integrity.26,27 In line 
with its physiological function,28 TF is normally expressed by subendothelial cells (i.e. adventitia and 
to lesser extent in medial cells of the arterial wall), which are not in direct contact with circulating 
coagulation factors. However, a growing number of evidence suggests that TF may also be induced by 
inflammatory molecules or be present in an inactive form (encrypted) in endothelial and circulating 
cells.14, 28, 29 In this respect, the present study found that TF within the arterial wall was augmented in 
Apold1-/- mice. This result indicates that increased vascular TF activity may be a primary contributor to 
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arterial thrombosis, thereby supporting previous research implying a greater contribution of vessel 
wall versus hematopoietic-produced TF to thrombus formation.30  
The lack of a cell-type specific knockout model limits our ability to ascertain which cell type is 
responsible for the prothrombotic phenotype observed in Apold1-/-  mice. However, considering that 
the endothelium is the only vascular cell in which Apold-1 is expressed,12 it is reasonable to infer a 
predominant endothelium-dependent increase in vascular TF activity. In this regard, several reports 
have described a major contribution of endothelium-derived TF to arterial thrombosis.4, 16, 29 
Endothelial TF can be regulated at transcriptional as well as posttranscriptional levels.31 In this study, 
TF mRNA levels were not different between groups, consistent with our finding of unaltered MAPKs 
activation in  Apold1-/- mice. Conversely, the PI3K/Akt pathway, a negative regulator of endothelial 
TF at both transcriptional and posttranscriptional levels, was decreased in Apold1-/- mice; thus, the 
decreased activation of the PI3K/Akt pathway could at least in part explain the increased TF activity 
observed in Apold1-/-  mice. Nevertheless,  we cannot rule out an alteration in the activation status 
(encryption/decryption) of TF, as observed in other studies.29, 32 Notwithstanding, this hypothesis is 
difficult to test due to the lack of knowledge on the underlying mechanisms of this process. 
Another important result of this study is that Apold1-/-  mice display an isolated platelet phenotype 
which, in concert to the augmented vascular TF activity, provides a possible explanation for the 
increased thrombogenicity observed in Apold1-/-  mice. Our results indicate that Apold1-/- deficiency 
increases platelet reactivity in response to the physiological agonist collagen, which plays a key role in 
the initial platelet response in atherothrombotic events. Platelets specifically and firmly bind to 
collagen via their glycoprotein VI (GPVI) receptor, which undergoes activation upon ligand binding. 
Thereafter, platelet degranulation with ensuing autocrine and paracrine stimulation, P-selectin 
exposure, and conformational activation of the platelet fibrinogen receptor GPIIb/IIIa mediate 
formation of the platelet thrombus.  
Thus, the increased sensitivity to collagen may be explained by alterations in the number or affinity of 
platelet GPVI or by alterations in platelet-signalling, which could influence platelet degranulation, 
platelet thromboxane 2 generation and GPIIb/IIIa receptor activation.33 Thus, further research will be  
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needed to elucidate the mechanisms by which Apold1 regulates platelet function, starting with 
assessing platelet reactivity in response to other agonists, such as thrombin and ADP. However, in the 
context of atherothrombosis with exposure of subendothelial collagen as a key pathophysiological 
feature, increased platelet sensitivity to collagen is of utmost importance. Noteworthy, these 
experiments were performed on washed platelets, thereby excluding plasmatic or vascular influences 
on platelet activation – most importantly, platelet activation via the TF-thrombin pathway. Thus, 
platelets may play a key role in the prothrombotic phenotype observed in Apold1-/-mice. Additional 
experiments using aspirin and FXa inhibitor may be an elegant way to determine the contribution 
of the observed platelet and coagulation phenotype to thrombus formation. 
In summary, this study demonstrates that Apold1 deletion increases coagulation and thrombus 
formation. Specifically, Apold1 deficiency increased vascular TF activity and enhanced platelet 
reactivity to collagen in a  mouse model of acute carotid artery thrombosis. Findings of the present 
study call for further investigation to assess the potential role of  Apold1 as a novel therapeutic target 
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Figure 1: Apold1 deficiency accelerates time to carotid thrombotic occlusion in vivo. (A, B , C) 
Body weight, blood flow and heart rate in WT and Apold1−/− mice. (D) Representative mean blood 
flow recordings of WT and Apold1-/- mice after in vivo photochemical injury. Occlusion was defined as 
blood flow below 0.1 mL/min for at least 1 min. (E) Time to thrombotic occlusion in WT and 
Apold1−/− mice. Data are expressed mean ± SEM. *P <0.05 
Figure 2: Effect of Apold1 deficiency on TF gene expression, TF activity, MAPKs and Akt 
signaling pathways. (A) TF mRNA expression in mouse aorta from Apold1−/− and WT mice. (B) TF 
activity in carotid arteries and (C) plasma of WT and Apold1−/− mice (D, E, F,G) Western blot of 
MAPKs (p38, JNK and ERK) and Akt pathway in mouse aorta from Apold1−/− and WT mice. Data are 
expressed mean ± SEM. *P <0.05 
Figure 3: Apold1 deficiency enhances platelet reactivity to collagen. (A,B) Platelet counts and 
volumes in WT and Apold1−/− mice (C) Deficiency of Apold 1 enhance collagen (5 µg/ml)-induced 
platelet aggregation demonstrated by increased maximal aggregation, (D) increased rate (slope) of 
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